Accuray (NASDAQ:ARAY) Stock Price Crosses Above 200-Day Moving Average - Time to Sell?

Key Points

• Accuray's stock price recently crossed above its 200-day moving average, trading as high as $1.79, and currently sits at $1.72.
• Equities analysts have given Accuray a consensus rating of "Buy" with a price target increase from $4.00 to $5.00 by BTIG Research.
• In its latest earnings report, Accuray missed EPS estimates, posting $0.01 compared to the $0.03 expected, despite exceeding revenue expectations with $127.54 million.

Accuray Incorporated (NASDAQ:ARAY - Get Free Report) crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $1.51 and traded as high as $1.79. Accuray shares last traded at $1.72, with a volume of 797,702 shares trading hands.

Analyst Ratings Changes

Several equities analysts recently issued reports on ARAY shares. BTIG Research boosted their price target on shares of Accuray from $4.00 to $5.00 and gave the company a "buy" rating in a research report on Thursday, August 14th. Wall Street Zen upgraded shares of Accuray from a "sell" rating to a "hold" rating in a report on Saturday, September 13th. One research analyst has rated the stock with a Buy rating, According to MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $5.00.

Accuray Trading Down 3.9%

The firm has a market capitalization of $193.80 million, a PE ratio of -86.00 and a beta of 1.26. The company has a quick ratio of 0.92, a current ratio of 1.65 and a debt-to-equity ratio of 1.53. The stock's fifty day simple moving average is $1.48 and its 200 day simple moving average is $1.51.

Accuray (NASDAQ:ARAY - Get Free Report) last announced its earnings results on Wednesday, August 13th. The medical equipment provider reported $0.01 EPS for the quarter, missing analysts' consensus estimates of $0.03 by ($0.02). Accuray had a negative net margin of 0.35% and a negative return on equity of 4.92%. The business had revenue of $127.54 million for the quarter, compared to analysts' expectations of $123.78 million. Accuray has set its FY 2026 guidance at EPS. On average, sell-side analysts predict that Accuray Incorporated will post 0.01 earnings per share for the current year.

Institutional Trading of Accuray

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Nuveen LLC purchased a new stake in Accuray during the first quarter valued at approximately $609,000. Hsbc Holdings PLC increased its stake in shares of Accuray by 15.4% in the first quarter. Hsbc Holdings PLC now owns 122,654 shares of the medical equipment provider's stock worth $221,000 after purchasing an additional 16,389 shares in the last quarter. Northern Trust Corp increased its stake in shares of Accuray by 0.9% in the fourth quarter. Northern Trust Corp now owns 809,665 shares of the medical equipment provider's stock worth $1,603,000 after purchasing an additional 7,399 shares in the last quarter. Ameriprise Financial Inc. purchased a new stake in shares of Accuray in the fourth quarter worth $35,000. Finally, Two Sigma Advisers LP increased its stake in shares of Accuray by 41.9% in the fourth quarter. Two Sigma Advisers LP now owns 70,513 shares of the medical equipment provider's stock worth $140,000 after purchasing an additional 20,813 shares in the last quarter. 64.08% of the stock is owned by hedge funds and other institutional investors.

About Accuray

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.